Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of th
AbbVie has announced its second major takeover deal in the space of a few days, offering $8.7 billion to buy central nervous system drug specialist Cerevel Therapeutics, w
Germany’s Merck KGaA is facing a big hole in its late-stage pipeline after multiple sclerosis (MS) candidate evobrutinib missed the mark in two phase 3 trials, spelling th
Sanofi has deepened an existing collaboration with artificial intelligence specialist Aqemia in the latest among a flurry of collaborations between pharma companies and ge
A few years ago, Roche abandoned the development of its lead PIK3CA-targeting drug taselisib on safety grounds, allowing rival Novartis to beat it to market, but now it ha
Alto Neuroscience has said its therapeutic approach to depression of matching patients to drugs based on brain biomarkers has shown promise in a phase 2a trial.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.